红状腺克鲁佩尔样因子 (KLF1):一种令人惊的多功能红状腺分化调节剂
James J Bieker1, Sjaak Philipsen2
1Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. james.bieker@mssm.edu.
Advances in experimental medicine and biology
|July 17, 2024
概括
红状腺克鲁佩尔样因子 (KLF1) 对于红细胞发育至关重要,作为激活剂和抑制剂. 人类KLF1变种导致各种血液疾病,突出显示其在红色素形成中的复杂作用.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 红色素克鲁佩尔样因子 (KLF1) 是一种红色素受限的转录因子,对红细胞产生至关重要.
- 最初以调节HBB基因而闻名,现在已经认识到KLF1在编排红色素形成中的更广泛作用.
研究的目的:
- 提供KLF1研究的概述,从它的发现到目前的理解.
- 讨论人类KLF1变异及其相关的红色球体表型的意义.
主要方法:
- 对KLF1功能和变体的现有文献的审查.
- 分析KLF1在基因调节中的作用,包括增强剂/促进剂相互作用.
- 检查临床数据,将KLF1变体与血液学疾病联系起来.
主要成果:
- KLF1在红色素形成中充当主调节剂,同时起到激活剂和抑制剂的作用.
- KLF1参与增强剂-促进剂循环形成,这是转录因子的新发现.
- KLF1变体与一系列红色球体表型有关,包括胎儿血红蛋白遗传性持久性,In(Lu) 血型,非球球性血液溶解性贫血症和IV型先天性失血性贫血症.
结论:
- KLF1是一种通用的转录因子,对正常的红色素形成至关重要.
- 了解KLF1的功能及其变体的影响对于诊断和潜在治疗相关血液疾病至关重要.
相关概念视频
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Maintenance of the ES Cell State
2.2K
The cells of the blastocyst inner cell mass only remain pluripotent for a short time. This state of pluripotency and self-renewal can be maintained in embryonic stem (ES) cell culture by adding specific chemicals or growth factors to ensure the cells can continue dividing and later differentiate into different cell types. In some cases, the cells are grown on a feeder layer of differentiated cells, which provides the growth factors and extracellular matrix components necessary for stem cell...
2.2K
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
General Transcription Factors
5.2K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
5.2K
Transcription Factors
75.8K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
75.8K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K


